BH 30643
Alternative Names: BH-30643Latest Information Update: 04 Nov 2025
At a glance
- Originator BlossomHill Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 24 Oct 2025 Efficacy and pharmacokinetics data from a phase-I/II SOLARA trial in Non-small cell lung cancer released by BlossomHill Therapeutics
- 22 Oct 2025 Updated efficacy, adverse events and pharmacokinetics data from the phase I/II SOLARA trial in Non-small cell lung cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025)
- 30 May 2025 Pharmacodynamics data from a preclinical studies in Non-small cell lung cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology, 2025 (ASCO-2025)